



ASX/NASDAQ ANNOUNCEMENT

Benitec Biopharma to Present at Biotech Showcase™ 2017 in San Francisco

Sydney Australia, 6 January 2017: Benitec Biopharma Limited (ASX: BLT; NASDAQ: BNTC; NASDAQ: BNTCW) today announced that Dr Cliff Holloway, Chief Business and Operations Officer, will present at the 9th Annual Biotech Showcase™ in San Francisco, CA during the J.P. Morgan Healthcare Conference. The presentation will take place on 9 January 2017 at the Hilton Union Square in Room 2.

The presentation will provide updates on the recent strategic collaboration with NantVentures to develop a novel anti-EGFR, oncology-focused platform and on the Company's ddRNAi gene-silencing technology programs, including the latest progress in the hepatitis B program.

A copy of the presentation will be posted to the Company's website following the event.

Management will be available for one-on-one meetings through the conference. Should you have interest in meeting with the Company at the conference, please contact a member of the Benitec investor relations team below.

Greg West, Chief Executive Officer, stated, "We finished 2016 with positive announcements on progress with the Nant relationship and on our pipeline, notably hepatitis B. The Company is now strongly positioned to capitalise on these developments in the year ahead. We look forward to sharing our corporate overview, summary of recent milestones and outlook during the conference."

For further information regarding Benitec and its activities, please contact the persons below, or visit the Benitec website at www.benitec.com.

Australia Investor Relations

Market Eye
Orla Keegan
Director
Tel: +61 (2) 8097 1201
Email: orla.keegan@marketeye.com.au

United States Investor Relations

M Group Strategic Communications
Jay Morakis
Managing Director
Tel: +1 212.266.0190
Email: jmorakis@MGroupSC.com



About Benitec Biopharma Limited:

Benitec Biopharma Limited (ASX: BLT; NASDAQ: BNTC; NASDAQ: BNTCW) is a biotechnology company developing innovative therapeutics based on its patented gene-silencing technology called ddRNAi or 'expressed RNAi'. Based in Sydney, Australia with laboratories in Hayward, California (USA), and collaborators and licensees around the world, the company is developing ddRNAi-based therapeutics for chronic and life-threatening human conditions including hepatitis B, wet age-related macular degeneration and OPMD. Benitec has also licensed ddRNAi to other biopharmaceutical companies for applications including HIV/AIDS, Huntington's Disease, chronic neuropathic pain and retinitis pigmentosa.

About Biotech Showcase™:

Biotech Showcase™ is an investor and networking conference devoted to providing private and public biotechnology and life sciences companies with an opportunity to present to, and meet with, investors and pharmaceutical executives in one place during the course of one of the industry's largest annual healthcare investor conferences. Now in its ninth year, Biotech Showcase™ 2017 is expected to attract upwards of 3,000 attendees. The program includes lunch plenary sessions featuring top industry leaders and innovators speaking on industry- and time-relevant topics, as well as presentations from both private and public companies. The event is being held January 9-11, 2017 at the Hilton San Francisco Union Square.

Safe Harbor Statement:

This press release contains "forward-looking statements" within the meaning of section 27A of the US Securities Act of 1933 and section 21E of the US Securities Exchange Act of 1934. Any forward-looking statements that may be in the press release are subject to risks and uncertainties relating to the difficulties in Benitec's plans to develop and commercialize its product candidates, the timing of the initiation and completion of preclinical and clinical trials, the timing of patient enrolment and dosing in clinical trials, the timing of expected regulatory filings, the clinical utility and potential attributes and benefits of ddRNAi and Benitec's product candidates, potential future out-licenses and collaborations, the intellectual property position and the ability to procure additional sources of financing. Accordingly, you should not rely on those forward-looking statements as a prediction of actual future results.